Agenus Inc. (NASDAQ:AGEN) will hold its 3Q20 earnings conference call with the financial community on 29th October 2020 at 8:30 AM Eastern Time.
The conference call will be webcast live on Internet at agenusbio.com
Earnings Expectation
Agenus Inc. is reporting third quarter financial results on Thursday 29th October 2020, before market open.
According to analysts surveyed by Thomson Reuters, AGEN is expected to report 3Q20 loss of $ 0.26 per share from revenue of $ 14.00 million.
For the full year, analysts anticipate top line of $ 70.74 million, while looking forward to loss of $ 1.02 per share bottom line.
Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodys immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others.
